BlackRock reduced its stake in Innovent Bio (01801.HK) by approximately 1.0021 million shares at an average price of about HK$82.91 per share.

The latest number of shares held after the reduction is approximately 86.7411 million, representing a holding ratio of 4.99%.

Zhitong Finance19:11

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

PR Newswire16:30

Hong Kong Market Moves | Innovative Drug Stocks Under Broad Pressure as Tighter Liquidity Directly Weighs on Sector Valuations; Institutions Note BINSA Draft Impact Is Largely Sentiment-Driven

Innovative drug-related stocks came under broad pressure. As of the time of writing, Innovent Bio (01801) fell 4.9% to HK$72.85; 3SBio (01530) dropped 3.44% to HK$15.14; Sinopharm Group (01177) declined 3% to HK$4.52; and CSPC Pharma (01093) slid 2.49% to HK$7.06.

Zhitong Finance15:08

Oriental Securities: Domestic Innovative Drugs Are Driving a Paradigm Shift in First-Line Treatment for NSCLC

Domestically developed innovative drugs achieved significant breakthroughs at this year's ASCO meeting, demonstrating strong competitiveness. It is recommended to pay attention to innovative drug companies with international competitive advantages.

Zhitong Finance09:55

Citi: Market Overreacts to Potential Restrictions on Biopharmaceutical Technology Exports, Creating a Buying Opportunity

Citi published a report stating that on June 4 (yesterday), it hosted an expert conference call with a senior pharmaceutical innovation policy specialist. According to the expert, regulators have recognized that the industry’s core competitive advantage lies in efficient clinical validation rather than technological invention per se; therefore, regulatory authorities will continue to encourage compliant out-licensing of innovative drugs. Stricter regulatory measures will apply only to extreme cases involving core technology exports. The expert also noted that companies with offshore IP structures, offshore clinical trial data, and a single-asset licensing model are best positioned. The firm’s top pick in the pharmaceuticals/biotech sector is Hengrui Pharma (012

AASTOCKSJun 5 10:58

CICC: Three Factors Cause Recent Underperformance of the Healthcare Sector; Top Picks Include Innovent Bio (01801.HK), Hansoh Pharmaceutical (03692.HK), and ConnoRheum (02162.HK)

China Merchants Securities International stated in a report that since May, the Hang Seng Healthcare Index has underperformed the Hang Seng Index by approximately 1,300 basis points, making it the largest drag on the market and signaling the sector’s entry into a downturn. The firm attributes the recent significant underperformance of the Hong Kong-listed pharmaceuticals/biotech sector to three factors: liquidity constraints, heightened policy uncertainty surrounding business development (BD) collaborations, and valuation markdowns on certain clinical-stage assets. At the macro level, amid increasing market bifurcation, liquidity has continued flowing into AI-themed stocks, driving their substantial outperformance, while other sectors have experienced notable valuation compression. Secondly, overseas BD transactions for Chinese innovative drugs face...

AASTOCKSJun 5 10:30